Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 9/20 | 0.42 |
| ▸ | GCGR | P47871 | 4/20 | 0.42 |
| ▸ | GIPR | P48546 | 2/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719474 | 0.94 | GCG (0.47) | GCGGCGRGIPRGLP1RKDM4E | |
| SCHEMBL717442 | 0.88 | KDM4E (0.42) | GCGGCGRGIPRGLP1RKDM4E | |
| SCHEMBL717935 | 0.84 | GCG (0.51) | GCGGCGRGIPRGLP1R | |
| SCHEMBL716584 | 0.83 | HIF1A (0.40) | GCGKDM4EKDM5BHIF1AEPAS1 | |
| SCHEMBL718408 | 0.83 | GCG (0.51) | GCGGCGRGIPRGLP1R | |
| SCHEMBL720849 | 0.81 | GCGR (0.53) | GCGGCGRGIPRGLP1R | |
| SCHEMBL718915 | 0.81 | GCG (0.55) | GCGGCGRGIPRGLP1R | |
| SCHEMBL718348 | 0.81 | GCG (0.48) | GCGGCGRGIPRGLP1R | |
| SCHEMBL718329 | 0.79 | GCG (0.51) | GCGGCGRGIPRGLP1R | |
| SCHEMBL717731 | 0.79 | HIF1A (0.38) | KDM4EKDM5BHIF1AEPAS1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GCGR 90/4885GIPR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.